Notably, trials of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists are also changing the trajectory of evidence in kidney diseases [15, 16]. Here, SLC5A2 is linked to kidney disorder.